Related Experiment Video
Updated: May 23, 2026

Analysis of HBV-Specific CD4 T-cell Responses and Identification of HLA-DR-Restricted CD4 T-Cell Epitopes Based on a Peptide Matrix
Published on: October 20, 2021
HBV mutations and their clinical significance
T W Lapiński1, J Pogorzelska, R Flisiak
1Department of Infectious Diseases and Hepatology, Medical University of Bialystok, Poland. twlapinski@wp.pl
Purpose:
The launch of the vaccine against HBV in 1983 significantly reduced the number of HBV infections in the world. But there still remain a large group of people with chronic hepatitis B who were infected before beginning of vaccination programs or in whom the vaccine was - for various reasons - ineffective. Current therapy of HBV infection based on PEG-IFN α-2a or nucleotide/nucleoside analogues does not guarantee sustained virologic response in the large majority of chronically infected persons. Treatment with some nucleoside analogues is associated with mutations and subsequent selection of resistant strains resulting with therapeutic failure, risk of cross-resistance to other drugs and finally selection of mutants with oncogenic properties.
More Related Videos
Related Concept Videos
Viral Mutations
Mutations in Microorganisms
Mechanisms of Retrovirus-induced Cancers
Rous Sarcoma Virus (RSV) and Cancer
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
Mutations
Chromosomal Alterations Are Large-Scale Mutations
While point mutations are changes in a single nucleotide in...
Mutations

